Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Bayer now says it expects to make €3 billion ... results of the phase 3 ARASENS trial in the New England Journal of Medicine. The study showed that adding Nubeqa to standard therapy with anti ...

Registered Dietitian & Nutritionist from Bayer, Kelly Bristow, Shares Expert Tips to Help You Kickstart Your <a target=_blank href= ...

Bayer cut its full-year earnings target after a tough agricultural market hit its crop-science division, and said it heads ...

According to The Wall Street Journal, Bayer started putting in the cotton ... More from Science We've all been there: reaching for the medicine cabinet with a splitting headache, opening the ...

Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co's rival drug gefapixant.

WHIPPANY, NJ, USA I January 14, 2025 I On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in ...

Leadership Strategist Dan Pontefract covers leadership and culture. Heike Prinz of Bayer's Board of Management recently articulated the company's predicament, stating, "Bayer is currently in a ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.